GoalVest Advisory LLC Sells 2,440 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• GoalVest Advisory LLC cut its Thermo Fisher Scientific stake by 93.8% in the second quarter, selling 2,440 shares and retaining 160 shares valued at approximately $80,000. Institutional investors collectively own 89.23% of TMO.
• Thermo Fisher reported stronger-than-expected quarterly results, with EPS of $6.03 and revenue of $11.99 billion; revenue increased 10.5% year over year. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $619.41.
• TMO opened at $593.11 and recently traded within a 52-week range of $435.27 to $643.99. The company declared a quarterly dividend of $0.47 per share, while insiders sold approximately $12.2 million in stock during the latest quarter.

GoalVest Advisory LLC cut its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 93.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 160 shares of the medical research company's stock after selling 2,440 shares during the quarter. GoalVest Advisory LLC's holdings in Thermo Fisher Scientific were worth $80,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in TMO. Legacy Wealth Managment LLC ID raised its stake in Thermo Fisher Scientific by 78.6% in the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company's stock valued at $25,000 after acquiring an additional 22 shares during the period. High Note Wealth LLC raised its position in shares of Thermo Fisher Scientific by 170.6% in the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company's stock valued at $27,000 after purchasing an additional 29 shares during the period. Swiss RE Ltd. purchased a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at approximately $28,000. JPL Wealth Management LLC bought a new position in Thermo Fisher Scientific in the 3rd quarter worth approximately $28,000. Finally, MBM Wealth Consultants LLC purchased a new position in Thermo Fisher Scientific in the 1st quarter valued at approximately $29,000. Hedge funds and other institutional investors own 89.23% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on TMO shares. KeyCorp restated an "overweight" rating on shares of Thermo Fisher Scientific in a research report on Tuesday, May 26th. Evercore set a $570.00 price objective on Thermo Fisher Scientific in a research note on Monday, July 6th. HSBC cut Thermo Fisher Scientific from a "buy" rating to a "hold" rating and dropped their price objective for the stock from $670.00 to $540.00 in a report on Wednesday, June 3rd. Sanford C. Bernstein assumed coverage on Thermo Fisher Scientific in a report on Friday, June 26th. They set a "market perform" rating and a $520.00 target price for the company. Finally, Piper Sandler raised their price objective on shares of Thermo Fisher Scientific from $510.00 to $600.00 and gave the company a "neutral" rating in a research report on Monday, July 27th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, Thermo Fisher Scientific has an average rating of "Moderate Buy" and an average target price of $619.41.

Thermo Fisher Scientific Price Performance

NYSE:TMO opened at $593.11 on Friday. Thermo Fisher Scientific Inc. has a 52-week low of $435.27 and a 52-week high of $643.99. The stock has a fifty day moving average of $517.63 and a 200 day moving average of $510.61. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. The firm has a market capitalization of $219.30 billion, a price-to-earnings ratio of 31.90, a P/E/G ratio of 2.42 and a beta of 0.85.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating the consensus estimate of $5.71 by $0.32. The firm had revenue of $11.99 billion for the quarter, compared to analysts' expectations of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The company's revenue was up 10.5% compared to the same quarter last year. During the same quarter last year, the firm posted $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, research analysts expect that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific's payout ratio is presently 10.11%.

Insiders Place Their Bets

In related news, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $574.47, for a total value of $5,744,700.00. Following the completion of the transaction, the chief executive officer directly owned 123,925 shares in the company, valued at approximately $71,191,194.75. The trade was a 7.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa P. Britt sold 5,850 shares of the stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $580.00, for a total value of $3,393,000.00. Following the completion of the transaction, the vice president directly owned 14,784 shares in the company, valued at approximately $8,574,720. This represents a 28.35% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 21,250 shares of company stock valued at $12,235,950 in the last quarter. Corporate insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source